The company immediately borrowed $255 million to pay part of the $680 million price tag for Alere's MeterPro cardiovascular and toxicology business and its BNP assay business.
The firm said that it expects to use the proceeds of the senior notes offering to contribute to retirement of remaining convertible notes.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
The infectious disease diagnostics firm will initially receive $40 million from CRG, most of which will go towards paying down existing debt.
The company borrowed $205 million in revolving loans from the credit facility, which matures on December 23, 2021.
The company said it will use the proceeds for various purposes, including working capital, capital expenditures, stock repurchases, dividends, and acquisitions.
The company took out the credit in connection with its $4.2 billion pending acquisition of electron microscopy firm FEI.
The firm did not disclose how it intended to use the $8 million, but said that it would provide temporary working capital.
The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.
The company said the draw down is to provide working capital to use on a temporary basis.
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.